Daniel Aires received his A.B. from Harvard College, his J.D. from Harvard Law School, and his M.D. from Yale Medical School. Prior to medical school, Aires worked as a McKinsey & Company consultant, providing strategic advice to Fortune 500 companies. Aires is now Director of the Division of Dermatology at the University of Kansas; before that he was on faculty at Harvard Medical School. He is a member of the Advisory Board of the American Academy of Dermatology and is a past President of the Kansas Dermatology Society. At HylaPharm he uses his combined business, medical, scientific, and legal backgrounds to work with investors, legal counsel, regulatory consultants, clinical research organizations, and scientists to move the technology forward.
LinkedIn
Laird Forrest, Ph.D., COO, is on faculty at the KU Department of Pharmaceutical Chemistry. Forrest developed the technology behind HylaPharm and founded HylaPharm. He supervises a federally- funded research program developing drug delivery technologies for cancer treatment. Dr. Forrest has published 51 papers in peer-reviewed journals and has taught drug development. He received his Ph.D. in Chemical and Biomolecular Engineering from the University of Illinois and postgraduate training at the University of Wisconsin. At HylaPharm he oversees the development of new molecules, the production of drugs for testing in animals and eventually humans, and coordination of animal trials.
LinkedIn
Craig Paddock, CFO, has more than 12 years of experience in marketing and business development as the president of Plaza Digital, a marketing and web-search optimization company. He directs web and related marketing campaigns for major clients, including Fortune 500 companies. He received his B.A. in Entrepreneurship from the University of Southern California. At HylaPharm his role is negotiation of contracts, financial planning, and investor recruitment.
LinkedIn
Chad Groer, Ph.D., CSO has specialized expertise in molecular, cellular, and behavioral pharmacology. He received a PhD in Pharmacology from The Ohio State University and post-doctoral training at The Scripps Research Institute (opioid pharmacology) and the University of Kansas (medical chemistry). Dr. Groer has received federal and state funding for drug development efforts of a novel opioid pain therapy and targeted cancer therapies. At HylaPharm, he is involved in all aspects of research and development for products targeting head and neck cancers and breast cancer.
LinkedIn